 recombin interferon alfa combin standard chemotherapi children acut lymphoblast leukemia first marrow relaps pediatr oncolog group pilot studi recombin interferon alfa rifn-alpha children acut lymphoblast leukemia first on-therapi marrow relaps sole treatment day standard four-drug reinduct multiag continu therapi consecut day week day rifn-alpha partial remiss pr addit patient equal reduct percentag marrow blast cell hypoplast marrow patient progress diseas increas leukocyt count patient influenza-lik symptom isol instanc sever abdomin pain person chang dose-limit toxic grade iii/iv transaminas elev patient syncop person chang patient children marrow remiss standard agent patient studi teniposid cytarabin ara-c consolid due toxic continu rifn-alpha puls children patient rifn-alpha dosag reduct cn toxic rifn-alpha toxic necessit reduct dose standard chemotherapi agent signific delay therapi patient remiss month patient marrow mening month mening mediastinum lymph node month children studi marrow transplant summari high-dos rifn-alpha alon modest antileukem effect contrast clinic experi combin rifn-alpha chemotherapi adult rifn-alpha pulse-lik manner continu therapi intens standard chemotherapi regimen